AXGN Axogen Inc.

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

Raymond James 47th Annual Institutional Investors Conference

Participation: Presentation and 1x1 investor meetings

Date/Time: Presentation Tuesday, March 3, 2026, 3:25 PM ET

Webcast Link: 

Leerink Global Healthcare Conference

Participation: Fireside Chat and 1x1 investor meetings

Date/Time: Fireside Chat Monday, March 9, 2026, 1:00 PM ET

Webcast Link: 

The Citizens Life Sciences Conference

Participation: Fireside Chat and 1x1 investor meetings

Date/Time: Fireside Chat Tuesday, March 10, 2026, 12:30 PM ET

Webcast Link: 

Webcast events can be accessed live through the  page at . For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at .

About Axogen

Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.​

Contact:

Axogen, Inc.



EN
17/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Axogen Inc.

 PRESS RELEASE

Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Resul...

Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter Financial Results Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarte...

 PRESS RELEASE

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Raymond James 47th Annual Institutional Investors ConferenceParticipation: Presentation and 1x1 investor meetingsDate/Time: Presentation Tuesday, March 3, 2026, 3:25 PM ETWebcast Link:  Leerink Global Heal...

 PRESS RELEASE

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Res...

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participa...

 PRESS RELEASE

Axogen Announces Pricing of Upsized $124 Million Public Offering of Co...

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition,...

 PRESS RELEASE

Axogen Announces Proposed Public Offering of Common Stock

Axogen Announces Proposed Public Offering of Common Stock ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 million of shares of its common...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch